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Objective: Our aim was to compare stentless and stented bioprostheses. Clinical out-
comes, hemodynamic performance, and postoperative left ventricular mass regression
were the principal outcomes assessed.
Methods: Sixty-two patients were recruited for the study. Our protocol was to con-
sider all patients older than 55 years for bioprostheses, and also younger patients
were implanted with a bioprosthesis if they wanted to avoid anticoagulation. Patients
selected for bioprostheses were randomly assigned to receive stentless (group A) and
stented (group B) bioprostheses, depending on the treating unit. Patients in groups A
and B were further divided into subgroups I and II based on left ventricular ejection
fractions of 50% or greater and less than 50%, respectively.
Results: At 18 6 3 months postoperatively, the effective orifice area was greater in
group A versus group B. Left ventricular ejection fraction, left ventricular mass index,
functional class, and mean gradient were similar in patients of subgroup I (left ventric-
ular ejection fraction.50%) from both groups. However, there was a significant dif-
ference between all except mean gradient in patients of subgroup II (left ventricular
ejection fraction ,50%) from both groups. Also, in the patient subgroup implanted
with valves of less than 19 mm (group A, 4 patients; group B, 3 patients), there
was a significant difference in left ventricular mass index and mean gradient.
Conclusion: In patients with left ventricular impairment or a small aortic annulus,
stentless bioprostheses might allow for greater improvement in left ventricular func-
tion postoperatively.
A
ortic valve replacement (AVR) is the treatment of choice for patients with
significant aortic valve disease. This procedure is associated with a low peri-
operative mortality, minimal morbidity, and good long-term outcomes. Elim-
ination of the sewing ring and stenting of conventional bioprosthetic valves have been
proposed to optimize the hemodynamic characteristics of the prosthesis. The intention
with these ‘‘stentless valves’’ was to maximize the area for blood flow across the
valve, which, in turn, might equate to superior hemodynamic performance through
lower postoperative transvalvular gradients. Furthermore, the absence of rigid stents
might allow diastolic forces to be more uniformly absorbed within the sinuses of Val-
salva, leading to reduced leaflet calcification and improved valve durability.1
Their design is postulated to impart characteristics that more closely emulate the
normal physiology of the aortic valve and root. It has been further suggested that
more favorable hemodynamic performance might lead to enhanced resolution of
left ventricular hypertrophy (LVH),2 a known potent cause of premature mortality.3,4
Modern stented valves have been shown to have excellent hemodynamic characteris-
tics.1,5 Previous randomized controlled trials have used a variety of stented and stent-
less valves, several of which are currently outmoded.6,7 Our aim was to conduct
a randomized controlled trial to compare widely accepted state-of–the-art stentless
and stented prostheses. Clinical outcomes, hemodynamic performance, and postoper-
ative left ventricular mass (LVM) regression were the principal outcomes assessed.
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AR 5 aortic regurgitation
AVR 5 aortic valve replacement
EOA 5 effective orifice area
LVEDD 5 left ventricular end-diastolic diameter
LVEF 5 left ventricular ejection fraction
LVH 5 left ventricular hypertrophy
LVM 5 left ventricular mass
LVMI 5 left ventricular mass index
Materials and Methods
Sixty-two patients were recruited for the study. Patients selected for
a bioprosthesis were randomly assigned to stentless and stented bio-
prostheses depending on the treating unit, with all patients in treating
unit A given a stentless bioprosthesis (group A, n 5 30) and all pa-
tients in treating unit B given a modern stented bioprosthesis (group
B, n 5 32). Patients in groups A and B were further divided into
subgroups I and II depending on left ventricular ejection fractions
(LVEFs) of 50% or greater and less than 50%, respectively.
All patients older than 55 years were considered for a bioprosthe-
sis. Patients younger than 55 years were implanted with a biopros-
thesis if they wanted to avoid anticoagulation. All patients with
aortic aneurysms, severely asymmetric aortic roots, annuloaortic ec-
tasia, active aortic valve infection, renal failure requiring dialysis,
and requirement for additional cardiac procedures were excluded
from the study.
All patients were implanted with valves of 19 mm or larger. The
Freestyle porcine tissue valve (Medtronic, Inc) has been used as
a stentless bioprosthetic valve, and the Carpentier–Edwards Peri-
mount Standard aortic valve (Edwards Life Sciences Corp) has
been used as a stented bioprosthesis. In patients with an aortic annu-
lus of less than 19 mm, the aortic root enlargement technique
(Nicks) was used to implant a 19-mm valve. Patients with very small
aortic roots requiring complex root enlargement procedures were
excluded. We have accepted the 19-mm valve size because of the
smaller average body surface area in our patients.
Stented valves were implanted with the continuous or interrupted
suture technique, and stentless valves were implanted with the inclu-
sion cylinder technique.
The inclusion cylinder implantation technique involves a proxi-
mal suture line (continuous or interrupted) like the subcoronary
technique in a circular plane coursing below the commissures. Gen-
erous openings are made by excising the sinuses facing the right and
left main coronary ostia. These are then tacked around the ostia,
much as a root inclusion Bentall procedure, with continuous 5–0
polypropylene sutures. The aortotomy is then closed in standard
fashion after trimming the device top down as necessary to incorpo-
rate the closure, making sure that the complete circle of the sinotub-
ular junction is left intact.
Postoperatively, all patients received 75 mg of aspirin as prophy-
laxis against thromboembolism. Patients were formally antico-
agulated only if there were specific indications, such as atrial
fibrillation. Clinical and echocardiographic parameters were re-
corded preoperatively, and functional status and echocardiographic
parameters were reevaluated. Mean follow-up was 18 6 3 months944 The Journal of Thoracic and Cardiovascular Surgery c Octfor both groups. Echocardiographic parameters recorded were effec-
tive orifice area (EOA), LVEF, left ventricular end-diastolic diame-
ter (LVEDD), mean gradient, and left ventricular mass index
(LVMI). Functional status was recorded in terms of NewYork Heart
Association functional class.
The protocol of the study was approved by the institutional
review board before the start of the study. Informed consent was
obtained from each patient before inclusion in the study.
The data have been expressed as means and standard deviations.
The Student t test has been used for statistical analysis.
Results
Preoperative demographic profile, clinical characteristics,
and echocardiographic parameters were comparable in both
groups (Table 1). Mean valve size implanted was 21.3 6
1.2 mm in group A and 21.4 6 1.3 mm in group B. One
patient in group A (subgroup II) and 1 patient in group B
(subgroup II) died of low cardiac output failure.
The EOA was greater in group A versus that in group B.
LVEF, LVMI, mean gradient, and New York Heart Associ-
ation functional status were similar in patients of subgroup
I (LVEF $50%) of both groups (Table 2). However, there
TABLE 1. Demographic profile, clinical characteristics,
and echocardiographic parameters
Group A
(n 5 30)
Group B
(n 5 32)
P
value
Age (y) 55 6 8 56 6 10 NS
Sex
Male 22 22 NS
Female 18 20 NS
NYHA class
I (A/B) 2/1 2/1 NS
II (A/B) 8/4 7/5 NS
III/IV (A/B) 9/6 10/7 NS
LVEF
$50% (A) 19 19 NS
A 165 6 21 162 6 19 NS
,50% (B) 11 13 NS
B 188 6 20 187 6 24 NS
LVMI (g/m2)
Ischemic time (min) 89 6 13 57 6 10 S
CPB time (min) 115 6 17 86 6 14 S
BSA (m2) 1.57 6 0.12 1.56 6 0.13 NS
Valve size implanted 21.3 6 1.3 21.5 6 1.4 NS
Cause
AS 19 22 NS
AR 11 10 NS
LVEDD in AS (cm) 5.1 6 0.8 5.2 6 0.7 NS
LVEDD in AR (cm) 6.4 6 1.1 6.3 6 1.1 NS
NS, Not significant (P . .05); NYHA, New York Heart Association; LVEF, left
ventricular ejection fraction; LVMI, left ventricular mass index; S, significant
(P# .05); CPB, cardiopulmonary bypass; BSA, body surface area; AS, aortic
stenosis; AR, aortic regurgitation; LVEDD, left ventricular end-diastolic
diameter.ober 2008
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cept mean gradient in patients of subgroup II (LVEF,50%)
from both groups (LVEF, 56% vs 45%; LVMI, 115 vs 140 g/
m2; and mean gradient, 8 vs 11 mm Hg), with more improve-
ment in functional status of patients of group A (subgroup II)
compared with those of group B (subgroup II; Table 3). In the
patient subgroup with a small aortic root who were implanted
with a 19-mm valve (group A, 4 patients; group B, 3 pa-
tients), although the number of patients was much less, there
was a significant difference in LVM, EOA, and mean gradi-
ent between this subgroup of patients of groups A and B
(LVMI, 117 vs 138 g/m2; mean gradient, 11 vs 25 mm Hg;
and EOA, 1.57 vs 1.34 cm2, respectively), with better func-
tional status in patients of group A (Table 4).
On performing multivariate analysis in patients with poor
left ventricular function (LVEF,50%), the type of valve im-
TABLE 2. Postoperative parameters of patients with LVEFs
of 50% or greater
Group A
(subgroup I;
n 5 19)
Group B
(subgroup I;
n 5 18) P value
LVEF (%) 61 6 5 59 6 4 S
EOA (cm2) 1.71 6 0.12 1.52 6 0.12 S
LVMI (g/m2) 110 6 12 118 6 13 NS
NYHA class
I 14 14 NS
II 5 4 NS
III/IV 0 0 NS
Mean gradient (mm Hg) 9 6 3 13 6 6 NS
LVEF, Left ventricular ejection fraction; S, significant (P#.05); EOA, effective
orifice area; LVMI, left ventricular mass index; NS, not significant (P . .05);
NYHA, New York Heart Association.
TABLE 3. Postoperative parameters of patients with LVEFs
of less than 50%
Group A
(subgroup II;
n 5 10)
Group B
(subgroup II;
n 5 12) P value
LVEF preop (%) 36 6 6 35 6 5 NS
LVEF postop (%) 52 6 6 43 6 5 S
LVMI (g/m2) 115 6 11 140 6 14 S
NYHA class
I 6 2 S
II 3 6 S
III/IV 1 2 NS
EOA (cm2) 1.69 6 0.08 1.53 6 0.09 S
Mean gradient (mm Hg) 8 6 3 11 6 3 NS
LVEF, Left ventricular ejection fraction; preop, preoperative; postop, postop-
erative; NS, not significant (P . .05); S, significant (P # .05); LVMI, left ven-
tricular mass index; NYHA, New York Heart Association; EOA, effective
orifice area.The Journal of Thoplanted and preoperative LVEDD were independent factors
for predicting postoperative improvement in left ventricular
function and LVM regression. All patients in this group
who were implanted with a stentless valve had significantly
more improvement in both these parameters postoperatively
compared with those who were implanted with stented
valves. All patients with aortic insufficiency and an LVEDD
of greater than 6.5 cm had less improvement in both these pa-
rameters postoperatively compared with those who had an
LVEDD of less than 6.5 cm preoperatively. Patients with aor-
tic stenosis and an LVEDD of greater than 5.5 cm had less
improvement in both these parameters postoperatively com-
pared with those who had an LVEDD of less than 5.5 cm pre-
operatively. Over a mean follow-up of 186months, we have
found that none of the patients in either group had moderate
or severe atrial regurgitation (AR), and only 2 patients in
group A and 2 patients in group B had mild AR.
Discussion
In population studies LVH has been associated with an in-
creased incidence of sudden death, myocardial infarction,
congestive heart failure, and consequently poorer long-term
survival than seen in age-matched control subjects.3 It has
been suggested that enhanced regression of LVH after
AVR might translate into clinical benefits. More complete
resolution of LVH could lead to improvements in long-
term survival. Observational studies have reported that stent-
less bioprostheses confer hemodynamic advantages after
AVR, which might allow for superior regression of LVH
and more favorable long-term outcomes in patients operated
on for aortic valve disease.1,7
Our inability to document any hemodynamic advantages
or superior LVM regression after stentless AVR parallels
the findings of other recent randomized trials.8-10 Newer-
generation stented valves have a lower profile and more
narrow sewing rings, which produce less impedance to trans-
valvular flow than older designs. Excellent hemodynamic
TABLE 4. Postoperative parameters of patients with a small
annulus
Group A (n 5 4) Group B (n 5 3)
EOA (cm2) 1.47 1.28
LVMI (g/m2) 117 138
NYHA class
I 3 2
II 1 3
III/IV 2 2
Mean gradient (mm Hg) 11 25
LVEF postop (%) 61 60
EOA, Effective orifice area; LVMI, Left ventricular mass index; NYHA, New
York Heart Association; LVEF, left ventricular ejection fraction; postop, post-
operative.racic and Cardiovascular Surgery c Volume 136, Number 4 945
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been documented by a number of investigators.1,5
It has been inferred that the use of a stentless bioprosthesis
might be particularly advantageous in the setting of preoper-
ative ventricular impairment. This is based on the findings of
a few investigators who suggest that stentless valves might
allow for greater improvement in left ventricular function
postoperatively.11-14 It has been demonstrated that early after
AVR, stentless prostheses allow for a greater and more im-
mediate reduction in left ventricular systolic wall stress.
This observation has been correlated with improved ventric-
ular function in the early postoperative period.11-14 This dif-
ference wanes after 12 months postoperatively, except in
patients with left ventricular impairment. Our randomized
study seems to substantiate this observation with a difference
in LVMI regression, and improvement in functional status
between groups A and B at a mean follow-up of 18 6 3
months was statistically significant in patients with left ven-
tricular impairment preoperatively. In patients with reduced
ventricular function, this finding might have important impli-
cations for long-term outcome. Also, we found that preoper-
ative LVEDD was an independent factor for improvement in
left ventricular function and LVM regression in patients with
an LVEF of less than 50%. All patients with AR and an
LVEDD of greater than 6.5 cm had less improvement in
both these parameters postoperatively compared with those
who had an LVEDD of less than 6.5 cm preoperatively.
Patients with aortic stenosis and an LVEDD of greater than
5.5 cm had less improvement in both these parameters post-
operatively compared with those who had an LVEDD of less
than 5.5 cm preoperatively. This finding is similar to that
shown by Tafreshi and colleagues,15 who demonstrated
end-diastolic dimensions to be an important predictor for
persistent postoperative left ventricular dysfunction.
In the present studywehave chosen to implant bioprosthetic
valves in patients older than 55 years. The age group in our
study is younger than that for bioprosthetic valve implantation
seen in other studies (ie,.65 years age). We have lowered the
age limit for implanting a bioprosthetic valve in our study
because of the lower average life expectancy in our country.
Our observations suggest that the routine use of stentless
bioprostheses over stented valves in all patients on the pre-
sumption that they confer hemodynamic advantages is un-
likely to be justified. However, in specific patient groups
undergoing AVR, stentless valves might provide important
benefits. We noted a trend toward improved hemodynamic
performance of stentless valves in patients with left ventricu-
lar impairment preoperatively and those with smaller aortic
annuli. In patients with an annular diameter of less than or
equal to 19 mm who were implanted with a 19-mm valve,
the mean systolic gradient was significantly lower in stentless
valve recipients, with significantly better functional status at
18 6 months postoperatively.14 However, this patient group
comprised only a small proportion of our entire study cohort.946 The Journal of Thoracic and Cardiovascular Surgery c OctIn our study patients receiving stentless valves had a signifi-
cantly greater EOA compared with those with stented valves
18 6 months after AVR. The absence of significant AR in
both groups at a mean follow-up of 18 6 months shows du-
rability of both these valve types; however, long-term follow-
up is required to substantiate this finding. Also, this study
suggests that patients with huge left ventricular dimensions
(LVEDD.6.5 cm in severe AR and.5.5 cm in severe aortic
stenosis) with an LVEF of less than 50% had less LVM re-
gression and functional improvement after AVR. Hence
these patients should undergo operations early before deteri-
oration in LVEF.
In conclusion, both stented and stentless bioprostheses
are associated with excellent clinical and hemodynamic
outcomes at a mean follow-up of 186 3months. Comparable
hemodynamics and LVM regression can be achieved with
a newer-generation stented bioprosthesis. In patients with
ventricular impairment and those with a small annulus, stent-
less bioprosthesesmight allow for greater improvement in left
ventricular function and greater improvement in functional
class postoperatively. Hence despite increased operative
time for implantation of stentless valves, this is the subgroup
of patientswhowere benefitedwith implantation of a stentless
valve. With studies showing long-term durability of stentless
valves13 and improved outcomes of redo operations, stentless
valves can be considered as a first option in younger patients
with left ventricular impairment orwith a small aortic annulus.
We also conclude that patientswith huge left ventricular di-
mensions should be operated on early before deterioration of
left ventricular function to achieve better postoperative results.
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